Nationally Recognized Heart Hospital
Dallas   Fort Worth

Find a Physician

Advanced Search

CLEAR: Evaluation of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo

Research area:
Principal investigator:
Cara East, MD, Medical Director, Soltero Cardiovascular Research Center
Type of study:

Study synopsis:
This is a randomized, double-blind, placebo-controlled study to assess the effects of bempedoic acid (ETC-1002) on the occurrence of major cardiovascular events in patients with, or at high risk for, cardiovascular disease who are statin intolerant.

Study objective:
The study is designed to determine if treatment with bempedoic acid (ETC-1002) versus placebo decreases the risk of cardiovascular events in patients who are statin intolerant. The primary outcome measure will be time from randomization to first occurrence of one of the following adjudicated composite endpoints: CV death, nonfatal myocardial infarction (MI), nonfatal stroke, or coronary revascularization.

Main/critical inclusion and exclusion criteria: A complete list of inclusion and exclusion criteria can be found at

Study contact:
Merielle Boatman, MBA, BAAS,, 214.820.2273.

Back to Clinical Trials